



Company Overview

BIOSHARES 25 July 2023
Otto Buttula – Executive Chairman



Disclaimer

This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Company Overview

Capital Structure

ASX Code	RHY
Share Price (at 18 July 2023)	\$0.47
Shares on Issue	219.8 M
Unlisted Options	12.9 M
Market Capitalisation	\$109 M
Cash in bank (31 March 2023)	\$6.8M
Top 20 Shareholders	41%

Share Price Chart



Board and Management

Otto Buttula	Trevor Lockett	Lou Panaccio	Rachel David	Sue MacLeman
Executive Chairman	Executive – Technical Director	Non-Executive Director	Non-Executive Director	Independent, Deputy Chair
<ul style="list-style-type: none"> Extensive financial, investment, IT and biotech experience. Co-Founder and CEO of IWL (ASX: IWL); Founder / former CEO of Investors Mutual. Formerly a Director of Imugene (ASX: IMU) and Chairman of Investorfirst, now HUB (ASX: HUB). Chairman of HITIQ (ASX: HIQ) and Oncosil Medical (ASX: OSL). 	<ul style="list-style-type: none"> Former Theme Leader Colorectal Cancer and Gut Health CSIRO. Leader – Personalised Health Group CSIRO. Inventor on seven commercially-licensed patent families. 	<ul style="list-style-type: none"> Chairman of Avita Medical (ASX: AVH). Non-executive Director of Sonic Healthcare (ASX: SHL). Chairman of NeuralDX. Non-executive Director of Adherium (ASX: ADR). Non-executive Director of Unison Housing. Former CEO Melb Pathology & Monash IVF. 	<ul style="list-style-type: none"> Currently the Chief Executive Officer (CEO) of Private Healthcare Australia (PHA). Previously: Senior Director Government Affairs, Policy and Market Access for Johnson & Johnson. Various senior roles with McKinsey, CSL and Pfizer (formally Wyeth). 	<ul style="list-style-type: none"> Non-executive member of Planet Innovation Holdings, ATSE and OMICO (Australian Genomic Cancer Medicines Ltd). Member of the NSW Innovation and Productivity Council. Fellow of the Australian Academy of Technology and Engineering (ATSE).

Agenda

- Rhythm Biosciences – Our Goal
- The Burden of Colorectal Cancer
- ColoSTAT® - a simple screening alternative
- Clinical Data
- Historical Challenges
- Rhythm's 12 Month Focus
- Rhythm's Long-term Focus

Our Company's Goal

“ *Rhythm Biosciences is committed to saving lives through early detection of cancers using simple and accurate diagnostic technology* ”


Early detection is critical to improving patient outcomes and reducing the global burden of cancer;

Developing alternative screening solutions for specific cancers via patient friendly, simple blood tests is our primary focus; and

Rhythm's initial product, ColoSTAT® is a **simple, affordable blood test** for the early detection of colorectal cancer for global mass-market screening.

Colorectal cancer (CRC) is treatable and often curable, yet is the second leading cause of cancer death globally

CRC is a **progressive** disease in which epithelial cells in the colon or rectum grow out of control²



Disease progression of colorectal cancer³

Progression to other organs

- CRC is generally asymptomatic; more than 50% of CRC cases are diagnosed at an advanced stage⁴⁻⁶
- CRC grows slowly over many years and has the potential to be detected early⁷
- When localised to the bowel, CRC is highly treatable and often curable⁸

Global burden in 2020:

1.93 million new cases and **~940,000 deaths**¹




CURRENT TESTING & SCREENING REGIME


In most countries, screening is recommended for those aged between 50-74 years old, with the primary method being a faecal immunochemical test (FIT), which is designed to test only for blood in the stool.

CRC INCIDENCE IS ON THE RISE IN THE YOUNGER POPULATION

Major markets show that **11-15% of people diagnosed with CRC are below the age of 50⁹**, posing a public health challenge, premature death and increased healthcare costs.^{1,10}

Participation in CRC screening remains suboptimal despite national programmes being in place in many countries worldwide

Market	Population	Age – Screening Population	Screening Method	Screening Participation Rate	Unscreened Population/ Opportunity	Screening Population based on RHY001 (40 to <85 yrs)	Screening Opportunity based on RHY001 (40 to <85 yrs)	Incidence of CRC
Europe (EU-27) [®]	455.1 mill	133.5 mill (50 -74 yrs)	FIT, Colonoscopy [‡]	38%	143.0 mill	192.9 mill	142.2 mill	341,419
UK (England, Scotland, Wales and Northern Ireland)	67.6 mill	10.6 mill (60 -74 yrs)	FIT	67%	3.5 mill	28.1 mill	21.0 mill	52,128
USA	331.9 mill	161.5 mill (45 – 75+ yrs)	FIT, Colonoscopy, [‡] Cologuard	61%	62.9 mill	181.3 mill	82.8 mill	153,020
Japan	123.3 mill [‡]	78.6 mill (> 40 yrs) [‡]	FIT	20%	48.2 mill	71.3 mill [‡]	55.6 mill	148,505
South Africa	59.4 mill	9.3 mill (50 -74 yrs)	FIT	NA		17.6 mill	17.6 mill	8,671**
Australia 	25.7 mill	7.1 mill (50 – 74yrs)	FIT	43%	4.0 mill	11.7 mill	8.8 mill	15,713
New Zealand	5.1 mill	1.1 mill (60 -74 yrs)	FIT	57%*	0.5 mill	2.3 mill	1.7 mill	> 3,000
Total		301.7 mill			216.8 mill	505.2 mill	329.6 mill	



[®] <https://ec.europa.eu/eurostat/databrowser/view/TPS00001/default/table?lang=en>

*Based on pilot project, recent data not available - <https://www.health.govt.nz/our-work/preventative-health-wellness/screening/bowel-screening-pilot/bowel-screening-pilot-results>

**https://journals.lww.com/ajig/Fulltext/2021/10001/S342_Evaluating_Trends_of_Colonorectal_Cancer.342.aspx

[‡] <https://www.populationpyramid.net/japan/2023/>

 <https://www.aihw.gov.au/reports/older-people/older-australians/contents/demographic-profile>

[‡] Every 10 years

FIT; faecal immunochemical test, NA; not available

Blood tests, such as ColoSTAT[®], are preferred by patients over FIT as they provide a more acceptable way to participate in testing


Blood-based tests are preferred over faecal tests (FIT) by 78–94% of people who are offered CRC testing¹⁻⁵, with ease and convenience being the main reasons for their preference³⁻⁴

In an observational study among 460 people in the US who were offered CRC testing¹:



Opted for a blood-based test[†] over FIT¹

In a randomized controlled trial, test uptake was significantly higher with a blood-based test[†] than with FIT ($p < 0.001$)²



Reasons for preferring blood-based options³⁻⁴:

- Convenience of a blood draw in the physician's office (74%; 67/90 patients)
- Ease/comfort of a blood test (78%; 71/90 patients)
- Lower time requirement vs FIT (48%; 43/90 patients)

Abbreviations: CRC, colorectal cancer; FIT, faecal immunochemical test [†]Blood-based test offered was Septin9 DNA blood test (Epi proColon[®])

1. Ioannou S, Sutherland K, Sussman DA, Deshpande AR. Increasing uptake of colon cancer screening in a medically underserved population with the addition of blood-based testing. *BMC Cancer*. 2021 Aug 28;21(1):966.


2. Liles GL, Coronado GD, Perrin N, Howel Harte A, Nungesser R, Quigley N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. *Cancer Treatment and Research Communications*. 2017;10:27-31.

3. Lamb HN, Dillon S. Epi proColon(R) 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. *Mol Diagn Ther*. 2017 Apr;21(2):225-32.

4. Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. *BMC Gastroenterol*. 2014 Oct 17;14:183.


5. Osborne JM, Wilson C, Moore V, Gregory T, Flight I, Young G. Sample preference for colorectal cancer screening tests: Blood or stool? *Open Journal of Preventive Medicine*. 2012;2(3):326-31.

ColoSTAT® - patented in 21 countries




ColoSTAT[®] - test kit explained

ColoSTAT[®] - indicated to screen adults, aged 40 to <85, at average risk for developing CRC. The test measures 5 specific biomarkers in the blood that either increase/decrease in concentration when CRC tumours are present.



ColoSTAT®* - simple four step procedure

COLOSTAT®



Our Clinical Data - prospective, multi-centre study to evaluate the clinical performance of the ColoSTAT[®] for the detection of CRC¹

Study Design

- The **primary endpoint** was to evaluate **ColoSTAT[®]** performance **compared to gold standard, colonoscopy.**
- 989 patients, aged 40 to <85 were included in the study.

Results

- ColoSTAT[®] met the primary endpoint and showed a high-sensitivity blood test for CRC detection.
- ColoSTAT[®] may provide an alternative test for people who cannot, or will not take the FIT test.

Sensitivity¹

81%


Specificity¹

91%

ColoSTAT[®] - development journey

ColoSTAT[®] is expected to increase participation, leading to earlier detection


ColoSTAT[®] Sensitivity Performance



- **Accurate**
ColoSTAT[®] obtains a qualitative likelihood of CRC presence based on 5 protein biomarker levels in the blood, compared to FIT (detects blood in the stool).
- **Affordable and Simple**
Cost-efficient simple blood test that may suited to screening programs.
- **Preferred**
A blood test is preferred over FIT because of ease and convenience.^{2,3}
- **Patient Friendly**
Convenient and can be part of routine health examination.

1. He et al DOI: 10.1200/JCO.2023.41.16_suppl.3529
2. Lamb YN, Dhillon S. Epi proColon((R)) 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. Mol Diagn Ther. 2017 Apr;21(2):225-32.
3. Adler A, Geiger S, Keil A, Bias H, Schatz P, deVos T, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014 Oct 17;14:183.

Strategic Pillars and Direction



DISRUPTIVE TECHNOLOGY

- An alternative to current screening methods through a well-established ELISA based technology.

GLOBAL CAPABILITY

- Manufacturing capability for our target markets.
- Increase production capacity with further international and local CMOs.

COMMERCIALISATION

- Commercial due diligence into international jurisdictions underway.
- USA – commercialisation pathway:
 - Lab Developed Test (LDT) via a CLIA Lab.
- Review additional regulatory requirements for IVDR and TGA submission.
- Raise awareness among younger demographics as 11-15% of patients diagnosed with colorectal cancers are less than 50 years of age.

PARTNERS

- Signed a collaborative UK partnership with LINK Medical Solutions.
- Developing further strategic partnerships in international jurisdictions.

Historical Challenges

- Test development - combining 5 different biomarker immunoassays into one kit
 - transitioning from research to commercial.
- Pandemic impact on:
 - Study recruitment; and
 - Manufacturing scale up.
- Market awareness:
 - Blood-based vs current screening methods, which have been in market for the past 3-4 decades.

Rhythm's 12 Month Focus

- FY'24 commercial sales – initially focused on ~1% of addressable market.

- UK market launch:
 - Establish ColoSTAT® as an alternative to FIT;
 - Developing partnerships with key labs for growth; and
 - Maximising sales revenue through the private market
 - Over 61% of CRC detected, are outside the current screening age.

- South African market entry;
- New Zealand market entry;
- USA market launch and strategy – finalise approach;
- Australian market - progression of regulatory approval;
- Transfer immunoassay to automated platform; and
- Development of other platform technologies.

Platform Technology Expansion – Stage 1



STAGE 1 Progression		Theoretical Analysis of Biomarker Potential	Serum and Algorithm Analysis	Risk Analysis → Enter Stage 2
Cancer Type	Collaborator			
Breast	Agilex Biolabs	[Progress bar: ~95%]		
Lung	Baker Institute	[Progress bar: ~75%]		
Stomach	Nexomics	[Progress bar: ~45%]		
Cervical	TBD	[Progress bar: ~30%]		
Pancreatic	TBD	[Progress bar: ~15%]		

Rhythm's Long-term Focus

- Establish ColoSTAT® as test of choice in CRC.
 - Expand test in diagnosis of advanced adenomas.
- Increase participation rate in CRC testing and reduce late diagnosis.
- Market awareness, widen CRC screening participation in individuals aged 40 and above.
- Machine agnostic.
- Recurring revenues across multiple markets.
- Expansion of platform technology to include multiple cancers.

Thank you

References

Slide 5

1. Xi Y, Xu P (2021), Global colorectal cancer burden in 2020 and projections to 2040, Translational Oncology, 14(10), 101174,doi:10.1016/j.tranon.2021.101174 Epub 2021 Jul 6
2. Center for Disease Control and Prevention (CDC). Colorectal cancer, available at: https://www.cdc.gov/cancer/colorectal/basic_info/what-is-colorectal-cancer.htm#:~:text=Colorectal%20cancer%20is%20a%20disease,the%20colon%20to%20the%20anus
3. Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Primers. 2015 Nov 5;1:15065.
4. Australia colorectal cancer statistics. Available at: <https://ncci.canceraustralia.gov.au/diagnosis/distribution-cancer-stage/distribution-cancer-stage>
5. ACS. Colorectal cancer facts and figure. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf>
6. Cancer Research UK. Early Diagnosis Data Hub. Available at: <https://crukancerintelligence.shinyapps.io/EarlyDiagnosis>
7. Better Health Channel. Bowel Cancer. Available at: Bowel cancer - Better Health Channel
8. National Cancer Institute. Colorectal Cancer. Available at: Colon Cancer Treatment (PDQ®)—Health Professional Version – NCI
9. <https://www.cancer.net/cancer-types/colorectal-cancer/risk-factors-and-prevention#:~:text=About%2011%25%20of%20all%20colorectal,cancer%20in%20the%20United%20States>
10. <https://www.cancer.org/research/acs-research-news/colorectal-cancer-rates-rise-in-younger-adults.html>